7 studies found for:    "Gastro-enteropancreatic neuroendocrine tumor"
Show Display Options
RSS Create an RSS feed from your search for:
"Gastro-enteropancreatic neuroendocrine tumor"
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting A Study of Famitinib in Patients With Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumor
Condition: Gastroenteropancreatic Neuroendocrine Tumor
Intervention: Drug: Famitinib
2 Recruiting Diagnostic Accuracy of Gallium-68-DOTATATE PET/CT Compared to Indium-111-pentetreotide Scintigraphy (SPECT/CT) for Gastroenteropancreatic Neuroendocrine Tumors
Condition: Gastroenteropancreatic Neuroendocrine Tumors
Interventions: Drug: Gallium-68-DOTATATE PET/CT (index test);   Drug: Indium-111-Octreoscan (standard test)
3 Recruiting TEP With 68-DOTANOC in Gastroenteropancreatic Neuroendocrine Tumors
Condition: Patients With Gastroenteropancreatic Neuroendocrine Tumors
Intervention: Drug: 68-Ga-DOTANOC
4 Recruiting 68Ga-OPS202 Study for Diagnostic Imaging of GEP NET
Condition: Gastroenteropancreatic Neuroendocrine Tumors
Intervention: Drug: 68Ga-OPS202
5 Active, not recruiting The Reproducibility Of Diffusion Weighted Magnetic Resonance Imaging For Neuroendocrine Tumor Liver Metastases
Conditions: Gastro-enteropancreatic Neuroendocrine Tumor;   Secondary Malignant Neoplasm of Liver
Intervention: Other: magnetic resonance imaging (MRI)
6 Active, not recruiting Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs
Condition: Gastroenteropancreatic Neuroendocrine Tumor of the Pulmonary ot Gastroenteropancreatic System
Interventions: Drug: Pasireotide LAR followed by Pasireotide LAR + Everolimus;   Drug: Everolimus followed by Pasireotide LAR + Everolimus
7 Recruiting 177Lutetium-octreotate Treatment Prediction Using Multimodality Imaging in Refractory NETs
Condition: Gastroenteropancreatic Neuroendocrine Tumors
Intervention: Drug: intravenous injection of 177Lu-octreotate

Indicates status has not been verified in more than two years